中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
9期
1060-1061
,共2页
范倩%李秀珍%邱明峰%刘暐%娄序笙%李冬梅%张秀静%鲁卫星
範倩%李秀珍%邱明峰%劉暐%婁序笙%李鼕梅%張秀靜%魯衛星
범천%리수진%구명봉%류위%루서생%리동매%장수정%로위성
心力衰竭%利钠肽,脑%超声心动描记术%心室功能,左
心力衰竭%利鈉肽,腦%超聲心動描記術%心室功能,左
심력쇠갈%리납태,뇌%초성심동묘기술%심실공능,좌
Heart failure%Natriuretic peptide,brain%Echocardiography%Ventricular function,left
目的 观察慢性心力衰竭(CHF)患者N末端B型利钠肽原(NT-proBNP)与心功能的相关性.方法 选择80例CHF患者为观察组,另选20例健康人为对照组.观察组采用β受体阻滞剂、血管紧张素转换酶抑制剂小血管紧张素受体拮抗剂等规范治疗,共28 d.比较治疗前后NT-proBNP浓度、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)各指标的变化.结果 ①对照组NT-proBNP为(87±23)ng/L,观察组NYHAⅡ、Ⅲ、Ⅳ级患者(分别为27、40、13例)治疗后NT-proBNP浓度均明显低于治疗前,差异均有统计学意义[(1913±707)ng/L比(2657±368) ng/L,(3403±1003) ng/L比(6037±1742 )ng/L,(6429±1348) ng/L比(8324±679) ng/L,均P＜0.01],均高于对照组(均P＜0.01)；②观察组治疗后LVEDD、LVESD和LVEF的水平均较治疗前改善,差异均有统计学意义[(49±9)mm比(53±8)mm,(33±9)mm比(39±10)mm,(58±9)％比(53±10)％,均P＜0.01]；③NT-proBNP与LVEDD及LVESD呈正相关(r值分别为0.640、0.694,均P＜0.01),与LVEF呈负相关(r=- 0.652,P＜0.01).结论 NT-proBNP与NYHA心功能分级、LVEDD、LVESD等有良好的相关性,NT-proBNP可用于CHF患者的临床诊断和疗效判定.
目的 觀察慢性心力衰竭(CHF)患者N末耑B型利鈉肽原(NT-proBNP)與心功能的相關性.方法 選擇80例CHF患者為觀察組,另選20例健康人為對照組.觀察組採用β受體阻滯劑、血管緊張素轉換酶抑製劑小血管緊張素受體拮抗劑等規範治療,共28 d.比較治療前後NT-proBNP濃度、左心室舒張末期內徑(LVEDD)、左心室收縮末期內徑(LVESD)、左心室射血分數(LVEF)各指標的變化.結果 ①對照組NT-proBNP為(87±23)ng/L,觀察組NYHAⅡ、Ⅲ、Ⅳ級患者(分彆為27、40、13例)治療後NT-proBNP濃度均明顯低于治療前,差異均有統計學意義[(1913±707)ng/L比(2657±368) ng/L,(3403±1003) ng/L比(6037±1742 )ng/L,(6429±1348) ng/L比(8324±679) ng/L,均P＜0.01],均高于對照組(均P＜0.01)；②觀察組治療後LVEDD、LVESD和LVEF的水平均較治療前改善,差異均有統計學意義[(49±9)mm比(53±8)mm,(33±9)mm比(39±10)mm,(58±9)％比(53±10)％,均P＜0.01]；③NT-proBNP與LVEDD及LVESD呈正相關(r值分彆為0.640、0.694,均P＜0.01),與LVEF呈負相關(r=- 0.652,P＜0.01).結論 NT-proBNP與NYHA心功能分級、LVEDD、LVESD等有良好的相關性,NT-proBNP可用于CHF患者的臨床診斷和療效判定.
목적 관찰만성심력쇠갈(CHF)환자N말단B형리납태원(NT-proBNP)여심공능적상관성.방법 선택80례CHF환자위관찰조,령선20례건강인위대조조.관찰조채용β수체조체제、혈관긴장소전환매억제제소혈관긴장소수체길항제등규범치료,공28 d.비교치료전후NT-proBNP농도、좌심실서장말기내경(LVEDD)、좌심실수축말기내경(LVESD)、좌심실사혈분수(LVEF)각지표적변화.결과 ①대조조NT-proBNP위(87±23)ng/L,관찰조NYHAⅡ、Ⅲ、Ⅳ급환자(분별위27、40、13례)치료후NT-proBNP농도균명현저우치료전,차이균유통계학의의[(1913±707)ng/L비(2657±368) ng/L,(3403±1003) ng/L비(6037±1742 )ng/L,(6429±1348) ng/L비(8324±679) ng/L,균P＜0.01],균고우대조조(균P＜0.01)；②관찰조치료후LVEDD、LVESD화LVEF적수평균교치료전개선,차이균유통계학의의[(49±9)mm비(53±8)mm,(33±9)mm비(39±10)mm,(58±9)％비(53±10)％,균P＜0.01]；③NT-proBNP여LVEDD급LVESD정정상관(r치분별위0.640、0.694,균P＜0.01),여LVEF정부상관(r=- 0.652,P＜0.01).결론 NT-proBNP여NYHA심공능분급、LVEDD、LVESD등유량호적상관성,NT-proBNP가용우CHF환자적림상진단화료효판정.
Objective To observe the correlation between N-terminal pro-brain natriuretic peptide (NT-proBNP)and cardiac function of chronic heart failure(CHF).Methods Eighty patients of CHF were chosen as the observation group,and were classified according to the NYHA classification standard.Twenty healthy people were chosen as control group.The results of NT-proBNP and echocardiography indexes,such as left ventricular enddiastolic dimension(LVEDD),left ventricular end systolic diameter (LVESD),left ventricular ejection fraction (LVEF)were compared.Results ①In the same grade of NYHA,compared with the baseline of the observation group,the results of NT-proBNP after treatment were much lower [ grade Ⅱ (1913±707 )ng/L vs (2657±368)ng/L,grade Ⅲ (3403±1003 )ng/L vs (6037±1742)ng/L,grade Ⅳ (6429±1348 )ng/L vs (8324±679)ng/L,all P＜0.01 ];②Compared with the baseline of the observation group,the results of indexes of echocardiography including LVEDD,LVESD and LVEF improved after treatment [ LVEDD (49±9 )mm vs (53±8)mm,LVESD(33±9)mm vs(39±10)mm,LVEF(58±9)％ vs(53±10)％,P ＜0.01 ];③NT-proBNP and LVEDD/LVESD were positively correlated (r =0.640,r =0.694,P ＜0.01 ),while NT-proBNP and LVEF had negative correlation (r=-0.652,P＜ 0.01 ).Conclusions NT-proBNP can be used in clinical diagnosis of CHF.NT-proBNP shows a good correlation to NYHA and echocardiography indexes.
